Why the study?
Does the presence of thrombophilia parameters impact long-term survival in patients with a history of venous thromboembolism?
Does the presence of thrombophilia parameters impact long-term survival in patients with a history of venous thromboembolism?
Classical hereditary thrombophilia risk factors do not impact long-term survival in VTE patients, supporting the concept that they should not determine long-term anticoagulation decisions, though hyperhomocysteinemia may increase mortality.
Classical thrombophilia should not yet guide anticoagulation duration in VTE; leaves open hyperhomocysteinemia's mortality association.
Data on the long-term survival following venous thromboembolism (VTE) are rare, and the influence of thrombophilia has not been evaluated thus far. Our aim was to assess thrombophilia-parameters as predictors for long-term survival of patients with VTE. Overall, 1,905 out-patients (99 with antithrombin-, protein C or protein S deficiency, 517 with factor V Leiden, 381 with elevated factor VIII and 160 with elevated homocysteine levels, of these 202 had a combination and 961 had none of these risk factors) were included in the study between September 1, 1994 and December 31, 2007. Retrospective survival analysis showed that a total of 78 patients (4.1%) had died during the analysis period, among those four of definite or possible pulmonary embolism and four of bleeding. In multivariable analysis including age and sex an association with increased mortality was found for hyperhomocysteinemia (hazard ratio 2.0 [1.1.-3.5]) whereas this was not the case for all other investigated parameters. We conclude that the classical hereditary thrombophilia risk factors did not have an impact on the long-term survival of patients with a history of VTE. Thus our study supports the current concept that thrombophilia should not be a determinant for decision on long term anticoagulation. However, hyperhomocysteinaemia, known as a risk factor for recurrent VTE and arterial disease, might impact survival.
No takes yet. Share an insight, caveat, or question.
Reitter-Pfoertner et al. (2012) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: